https://orcid.org/0000-0001-8980-2410
Current Appointments & Affiliations
Instructor in the Department of Medicine
·
2020 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2022 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database.
Journal Article Clin Genitourin Cancer · March 2026 INTRODUCTION: Enfortumab vedotin (EV)-based regimens have become standard treatments for advanced urothelial carcinoma (aUC). However, clinical trials excluded clinically significant peripheral neuropathy or uncontrolled diabetes mellitus. Therefore, we ch ... Full text Link to item CiteEfficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.
Journal Article Oncologist · November 11, 2025 BACKGROUND: Erdafitinib is approved for locally advanced/metastatic urothelial cancer (LA/mUC). As enfortumab vedotin (EV) plus pembrolizumab enters frontline management, outcomes with erdafitinib pre- and post-EV are clinically relevant but not specifical ... Full text Link to item CiteAbstract B006: Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC)
Conference Molecular Cancer Therapeutics · October 22, 2025 AbstractBackground:XmAb819 is a T-cell engaging bispecific antibody in development for patients with ccRCC. Despite advances in ... Full text CiteRecent Grants
TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2025 - 2031A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Context Therapeutics, Inc. · 2026 - 2031GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients with Solid Tumors that Harbor the p53 R175H Mutation
Clinical TrialPrincipal Investigator · Awarded by Clasp Therapeutics, Inc · 2025 - 2030View All Grants
Education
New York Institute of Technology, College of Osteopathic Medicine ·
2001
D.O.